Arthur D. Little: New Report Offers a Blueprint for Overcoming Bottlenecks and Unlocking the Full Potential of Digitalisation in the Chemical Industry
Digitalisation has the power to transform the European chemical industry, revolutionising the sector's solutions and enabling a circular, more sustainable economy in line with the EU Green Deal objectives. This exciting potential is highlighted in a new report from Arthur D. Little and Cefic, the European Chemical Industry Council, which details how technologies like artificial intelligence, big data, Internet of Things, digital twins, robotics, virtual/augmented reality, and blockchain can accelerate the industry's transformation.
The study titled "Digital Technologies for Sustainability in the European Chemical Industry", is the first ever attempt to outline how these technologies are used in the chemical sector and how they can be scaled up to make the chemical industry’s processes and products more sustainable .
Dr. Daniel Witthaut, Executive Director for Innovation at Cefic, emphasises that while the EU chemical industry has already implemented digitalisation in various applications, there is still much more that can be done:
“Digitalisation in the chemical industry is not new with multiple players already applying digital technologies in their fields. However, enormous opportunities exist for the industry to reach their sustainability goals faster through the application of the latest digital technologies – a journey that is just beginning for most players. And this is where we also need to work more closely with EU institutions to remove existing bottlenecks, improve data sharing and create a larger pool of homegrown talent to implement all these new technologies”.
According to the research, digital technologies can make the greatest contribution in five priority areas in both large and small companies in the EU: (1) process design and production for climate and circularity objectives, (2) sustainability assessment, (3) enabling materials and chemicals circularity through tracking and tracing, (4) sustainable product design, and (5) safe and efficient logistics and distribution.
Dr. Michaël Kolk, Managing Partner at ADL, adds: “Chemical companies in Europe are not only working on their own sustainability objectives, but also providing solutions that serve as enablers for many downstream industries to reach their own. The picture is complex, but we believe that collaboration via greater digitalisation is the way forward.”
The report also highlights a number of challenges that must be addressed to fully realise the potential of digital technologies. These include technological challenges such as data availability, interoperability, standardisation and cybersecurity as well as reluctance among companies to share data, financial costs, organisational issues, and a shortage of digital skills in the workforce. Greater collaboration between EU institutions and the chemical industry will be needed to address some of these bottlenecks.
The report is available for download here: https://tinyurl.com/2s4bztsb
END
About the report
Arthur D. Little and the European Chemical Industry Council (Cefic) joined forces to prepare this report, which summarises the views of digital technology experts from within and outside the chemical industry.
Recommendations from this report are based on the result of 15 individual interviews with senior digital and sustainability experts (e.g., chief digital officers or chief sustainability officers) as well as a survey of more than 70 experts from 50 companies that are broad representatives of the chemical industry in terms of type of business, size, and region.
To add cross-industry perspectives, the study also took into account input from more than 10 globally recognised digital technology experts outside the chemical industry.
About Cefic
Cefic, the European Chemical Industry Council, founded in 1972, is the voice of large, medium and small chemical companies across Europe, which provide 1.2 million jobs and account for approximately about 15% of world chemicals production.
About Arthur D. Little
Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.
Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.
For further information, please visit www.adlittle.com or www.adl.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005504/en/
Contact information
Media contact: Marina Mendes
Cefic
+32 499239522
mam@cefic.be
Media contact: Sue Glanville
Catalyst Comms
+44 7715 817589
Glanville.sue@adlittle.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
